External link, please review our disclaimer.

Tracing NET

NIDA Notes
October 2007
photo of a man looking depressed

Researchers have developed and successfully tested a new tool for studying the neurobiology of depression, attention deficit hyperactivity disorder, and stimulant abuse. Researchers will be able to use the tool, a new radiotracer, to map the location and circulation of a protein that plays a central role in those conditions: the norepinephrine transporter (NET). Drs. Yu-Shin Ding, Jean Logan, and colleagues at Brookhaven National Laboratory screened six molecules to see whether any of them did the things a radiotracer for NET must do: get into the brain, spread to regions of the brain with high concentrations of NET, bind selectively to the protein, and leave the brain in a reasonable amount of time. Of the six, (S,S)-[11C]methylreboxetine (MRB) was by far the best candidate, binding tightly and specifically to NET. The norepinephrine, dopamine, and serotonin transporters are disrupted in depression, attention disorders, and stimulant abuse. Researchers previously developed radiotracers for the dopamine and serotonin transporters; the ability to image all three transporters in the brain will allow researchers to determine the role of each neurochemical in the disorders.

Journal of Neurochemistry 94(2):337-351, 2005. [Abstract]

This page was last updated October 2007.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site